• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    National Research Corporation Announces First Quarter Results

    5/7/24 5:00:00 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $NRC alert in real time by email

    National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the first quarter 2024.

    CEO Commentary

    Michael Hays, Chief Executive Officer, commented: "NRC continues to be strongly positioned for growth in our expanding markets. Our decades of benchmarks and trusted thought leadership afford healthcare insights unavailable to most competitors, while our client service remains unmatched, and we continue to roll out innovative new products and technologies. Our mission to enhance outcomes and experiences for everyone in the healthcare journey, while improving our clients' bottom lines, provides true alignment with our clients.

    "Healthcare systems are facing unprecedented competition and financial pressure, magnifying the importance of every experience across their enterprise – consumer, patient, employee. Our clients want a broader experience perspective, greater strategic alignment, innovation, and actionable insights that deliver more value. Next quarter, we will launch an expanded product suite that extends across the experience spectrum, recognizing and responding to consumers, patients, and caregivers as unique individuals. Our thought leadership assets, used by hundreds of health care systems, will be coordinated under our new Chief Experience Officer, who will use her decades of health system leadership roles to deliver them in increasingly targeted ways. And our expanded sales and product technology teams are working intensely with clients to develop a new generation of solutions, many powered by generative AI, that push analytics to managers and real-time, actionable insights to front line associates. We expect to offer new AI features and solutions this year and to integrate them across our products and business over time."

    Financial Summary

    Linda Stacy, Principal Financial Officer, commented on the financial results, "During the first quarter, we made significant investments in our technology, sales and service teams as we prepared to launch new products and solutions later this year. For the balance of the year, we expect to continue building our AI and other technology capabilities, as well as our sales and thought leadership resources while seeking operating efficiencies."

    The Company continued to execute the entire range of capital allocation alternatives, including funding innovation and growth investments, dividends, and share repurchases. During the first quarter of 2024, the Company returned $18 million to stockholders in the form of dividends and stock repurchases. Funding for organic innovation and growth investments was $4 million consisting of facilities improvements and investments in our Human Understanding solutions. The Company is highly focused on product innovation and expects to see expansion in funding for innovation and growth investments for the remainder of the year.

    The Company had strong cash flow from operations during the first quarter of 2024 and, at March 31, 2024, had other sources of liquidity including borrowing availability of $23 million on its line of credit and $56 million on its delayed draw term facility. At March 31, 2024, the Company had approximately $40 million of net debt.

    Dividend

    The Company's Board of Directors has declared a quarterly cash dividend of $0.12 (twelve cents) per share payable Monday, July 15, 2024, to shareholders of record as of the close of business on Friday, June 28, 2024.

    Conference Call

    A live simulcast of National Research Corporation's 2024 first quarter conference call will be available online at https://events.q4inc.com/attendee/554254445 May 8, 2024, beginning at 11:00 a.m. Eastern time. The online replay will follow approximately one hour later and continue for 30 days.

    About NRC

    For more than 40 years, NRC Health (NASDAQ:NRC) has led the charge to humanize healthcare and support organizations in their understanding of each unique individual. NRC Health's commitment to Human Understanding® helps leading healthcare systems get to know each person they serve not as point-in-time insights, but as an ongoing relationship. Guided by its uniquely empathic heritage, NRC Health's patient-focused approach, unmatched market research, and emphasis on consumer preferences are transforming the healthcare experience, creating strong outcomes for patients and entire healthcare systems. For more information, email [email protected], or visit www.nrchealth.com.

    This press release contains certain statements that may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such statements are subject to the safe harbor created by those sections and the Private Securities Litigation Reform Act of 1995, as amended. Such statements may be identified by their use of terms or phrases such as "believes," "expect," "focus," "potential," "will," derivations thereof, and similar terms and phrases. In this press release, the statements related to the roll out of new products, thought leadership assets, future use of AI, investment in product innovation, sales, technology, and thought leadership resources, operating efficiency, client profitability, the potential to expand Human Understanding and increase market share, and future revenue growth, and capital allocation are forward-looking statements. Forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, which could cause future events and actual results to differ materially from those set forth in, contemplated by, or underlying the forward-looking statements, including those risks and uncertainties as set forth in the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, 2023, and various disclosures in our press releases, stockholder reports, and other filings with the Securities and Exchange Commission. We disclaim any obligation to update or revise any forward-looking statements to reflect actual results or changes in the factors affecting the forward-looking information.

     

    NATIONAL RESEARCH CORPORATION AND SUBSIDIARY

    Unaudited Condensed Consolidated Statements of Income

    (In thousands, except per share data)

     

     

    Three months ended

    March 31,

     

     

    2024

     

     

     

    2023

     

     

     

     

    Revenue

    $

    35,313

     

    $

    36,473

     

     

    Operating expenses:

     

     

    Direct

     

    13,856

     

     

    14,280

     

    Selling, general and administrative

     

    11,250

     

     

    11,783

     

    Depreciation and amortization

     

    1,447

     

     

    1,394

     

    Total operating expenses

     

    26,553

     

     

    27,457

     

     

     

     

    Operating income

     

    8,760

     

     

    9,016

     

     

     

     

    Other income (expense):

     

     

    Interest income

     

    44

     

     

    250

     

    Interest expense

     

    (605

    )

     

    (241

    )

    Other, net

     

    (5

    )

     

    (14

    )

     

     

     

    Total other income (expense)

     

    (566

    )

     

    (5

    )

     

     

     

    Income before income taxes

     

    8,194

     

     

    9,011

     

     

     

     

    Provision for income taxes

     

    1,835

     

     

    2,047

     

     

    Net income

    $

    6,359

     

    $

    6,964

     

     

     

     

    Earnings Per Share of Common Stock:

    Basic Earnings Per Share

    $

    0.27

     

    $

    0.28

     

    Diluted Earnings Per Share

    $

    0.27

     

    $

    0.28

     

     

     

     

    Weighted average shares and share equivalents outstanding

    Basic

     

    23,868

     

     

    24,585

     

    Diluted

     

    23,963

     

     

    24,738

     

     

    NATIONAL RESEARCH CORPORATION AND SUBSIDIARY

    Unaudited Condensed Consolidated Balance Sheets

    (Dollars in thousands, except share amounts and par value)

     

     

     

    March 31,

    2024

     

    December 31,

    2023

    Assets

     

     

     

     

    Current assets:

     

     

     

     

    Cash and cash equivalents

     

    $

    1,699

     

     

    $

    6,653

     

    Accounts receivable, net

     

     

    11,127

     

     

     

    12,378

     

    Other current assets

     

     

    7,188

     

     

     

    5,329

     

    Total current assets

     

     

    20,014

     

     

     

    24,360

     

     

     

     

     

     

    Property and equipment, net

     

     

    31,530

     

     

     

    28,205

     

    Goodwill

     

     

    61,614

     

     

     

    61,614

     

    Other, net

     

     

    7,753

     

     

     

    8,258

     

    Total assets

     

    $

    120,911

     

     

    $

    122,437

     

     

     

     

     

     

    Liabilities and Shareholders' Equity

     

     

     

     

    Current liabilities:

     

     

     

     

    Current portion of notes payable

     

    $

    7,504

     

     

    $

    7,214

     

    Line of credit

     

     

    7,000

     

     

     

    --

     

    Accounts payable and accrued expenses

     

     

    8,129

     

     

     

    6,194

     

    Accrued compensation

     

     

    5,385

     

     

     

    3,953

     

    Deferred revenue

     

     

    15,194

     

     

     

    14,834

     

    Dividends payable

     

     

    2,865

     

     

     

    2,906

     

    Other current liabilities

     

     

    2,773

     

     

     

    1,102

     

    Total current liabilities

     

     

    48,850

     

     

     

    36,203

     

     

     

     

     

     

    Notes payable, net of current portion and unamortized debt issuance costs

     

     

    27,569

     

     

     

    29,470

     

    Other non-current liabilities

     

     

    7,547

     

     

     

    7,809

     

    Total liabilities

     

     

    83,966

     

     

     

    73,482

     

     

     

     

     

     

    Shareholders' equity:

     

     

     

     

    Preferred stock, $0.01 par value, authorized 2,000,000 shares, none issued

     

     

    --

     

     

     

    --

     

    Common stock, $0.001 par value; authorized 110,000,000 shares, issued 31,078,202 in 2024 and 31,002,919 in 2023, outstanding 23,877,315 in 2024 and 24,219,887 in 2023

     

     

    31

     

     

     

    31

     

    Additional paid-in capital

     

     

    179,929

     

     

     

    178,213

     

    Retained earnings (accumulated deficit)

     

     

    (27,036

    )

     

     

    (30,530

    )

     

     

     

     

     

    Treasury stock

     

     

    (115,979

    )

     

     

    (98,759

    )

    Total shareholders' equity

     

     

    36,945

     

     

     

    48,955

     

    Total liabilities and shareholders' equity

     

    $

    120,911

     

     

    $

    122,437

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240507960874/en/

    Get the next $NRC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NRC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NRC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Rau Jason Russell

    3 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

    11/6/25 5:01:46 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 4 filed by Director Nunnelly John N

    4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

    10/21/25 7:20:15 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 4 filed by Director Wheeler Penny Ann

    4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

    10/21/25 7:18:01 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NRC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NRC Health Partners with Mosaic Life Care to Advance Patient Experience Across the Midwest

    Mosaic Life Care, a physician-led health system located in northwest Missouri, announced a new partnership with NRC Health, the leader in healthcare experience management. Together, the organizations will work to elevate patient and employee experience across Mosaic's system, reinforcing its vision for Mosaic to be the region's first choice and most trusted partner in healthcare. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202915784/en/Mosaic Life Care, a physician-led health system located in northwest Missouri, announced a new partnership with NRC Health, the leader in healthcare experience management. Together, the organ

    12/2/25 9:00:00 AM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    NRC Health Appoints David Burik as Executive Vice President, Strategic Insights

    Seasoned healthcare strategy leader to advance The Governance Institute and Market Insights NRC Health, the leader in healthcare experience management, today announced the appointment of David Burik as Executive Vice President, Strategic Insights, effective January 5, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120531393/en/NRC Health, the leader in healthcare experience management, today announced the appointment of David Burik as Executive Vice President, Strategic Insights, effective January 5, 2026. David joins NRC Health from Guidehouse, where he has served as partner and leader of the Center for Health Insigh

    11/20/25 9:00:00 AM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    NRC Health Partners with BJC HealthCare to Advance Experience Excellence Across a Unified Network

    NRC Health, the leader in healthcare experience management, is proud to announce a new partnership with BJC Health System, one of the nation's largest nonprofit integrated healthcare delivery organizations. The collaboration will unify and elevate patient and employee experiences across BJC's hospitals, clinics, and academic partners, reinforcing its mission to improve the health and well-being of the people and communities it serves through leadership, education, innovation, and excellence in medicine. Through this partnership, NRC Health will provide its Patient Experience, Leader, and Employee Rounding solutions—creating a consistent, data-driven foundation for improvement and connecti

    11/13/25 9:00:00 AM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NRC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Freeman Jordan Nicole bought $10,000 worth of shares (771 units at $12.97) (SEC Form 4)

    4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

    8/4/25 4:40:44 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Large owner Beans Patrick E bought $33,974 worth of shares (2,500 units at $13.59), increasing direct ownership by 8% to 35,003 units (SEC Form 4)

    4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

    5/13/25 11:30:22 AM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NRC
    SEC Filings

    View All

    SEC Form 10-Q filed by National Research Corporation

    10-Q - NATIONAL RESEARCH CORP (0000070487) (Filer)

    11/7/25 1:03:21 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    National Research Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NATIONAL RESEARCH CORP (0000070487) (Filer)

    10/27/25 5:03:13 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    National Research Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - NATIONAL RESEARCH CORP (0000070487) (Filer)

    8/28/25 4:09:44 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NRC
    Leadership Updates

    Live Leadership Updates

    View All

    NRC Health Appoints David Burik as Executive Vice President, Strategic Insights

    Seasoned healthcare strategy leader to advance The Governance Institute and Market Insights NRC Health, the leader in healthcare experience management, today announced the appointment of David Burik as Executive Vice President, Strategic Insights, effective January 5, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120531393/en/NRC Health, the leader in healthcare experience management, today announced the appointment of David Burik as Executive Vice President, Strategic Insights, effective January 5, 2026. David joins NRC Health from Guidehouse, where he has served as partner and leader of the Center for Health Insigh

    11/20/25 9:00:00 AM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    NRC Health Announces Shane Harrison as Chief Financial Officer

    National Research Corporation (NASDAQ:NRC), doing business as NRC Health, a publicly-traded leader in healthcare experience, is pleased to announce the appointment of Shane Harrison as its incoming Executive Vice President and Chief Financial Officer, effective on or about September 25, 2025. Chief Financial Officer Shane Harrison is a seasoned finance leader with more than 25 years of experience spanning corporate finance, investor relations, and strategic transactions. He most recently served as Senior Vice President – Finance and Investor Relations at PowerSchool, a leading K-12 education SaaS provider, since 2022. Prior to that, he served as Senior Vice President – Corporate Develop

    8/28/25 8:00:00 AM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    National Research Corporation Appoints Trent Green as Chief Executive Officer

    National Research Corporation (NASDAQ:NRC), doing business as NRC Health, a publicly-traded leader in healthcare improvement, is pleased to announce the appointment of Trent Green as its incoming Chief Executive Officer, effective June 1, 2025. Green will succeed Mike Hays, the company's current CEO, who will transition to the role of Chairman, ensuring a smooth leadership transition while maintaining NRC Health's mission-driven and shareholder-focused approach. Green brings more than 25 years of healthcare leadership experience, most recently serving as CEO of One Medical, San Francisco, CA, and previously as Chief Operating Officer at Legacy Health, Portland, OR. His expertise in care de

    3/4/25 4:01:00 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NRC
    Financials

    Live finance-specific insights

    View All

    NRC Health Announces Third Quarter 2025 Results

     Third quarter TRCV* increased 8% year-over-year to $141.7 million Cash flow from operations increased 46% year-over-year to $13.8 million National Research Corporation, dba NRC Health, (NASDAQ:NRC), a leader in healthcare experience improvement solutions, today announced results for the third quarter 2025. "We delivered our fourth consecutive quarter of recurring contract value growth, driven by strong sales and meaningful improvement in customer retention," said Trent Green, CEO of NRC Health. "This sustained momentum reflects how our solutions deliver insights, engagement, and enablement that help healthcare organizations better understand, anticipate, and respond to the experience

    10/27/25 5:00:00 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    NRC Health Announces Second Quarter 2025 Results

    Reports third consecutive quarter of sequential TRCV Growth National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the second quarter 2025. CEO Statement Trent S. Green, Chief Executive Officer of NRC Health, commented: "We're encouraged by our second-quarter results, which demonstrate continued momentum across key areas of our business. In my early weeks as CEO, I've been energized by feedback from both current and prospective customers, particularly their enthusiasm for our product portfolio and appreciation for the service mindset of our associates. To provide additional context on the quarter, we're reinstating our quarterly earnings call, which I

    7/28/25 5:00:00 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    NRC Health Announces First Quarter Results

    National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the first quarter 2025 and other corporate developments. Highlights: Total Recurring Value Contract Value Increases Sequentially Sales Force Expansion Accelerates New Share Repurchase Program Announced Operating Expenses Decline Dividend Declared Overview Michael D. Hays, Chief Executive Officer of NRC Health, commented on the Company's performance and recent developments: "The key milestone this quarter was a second consecutive quarter of sequential increase in total recurring contract value, which remains the leading indicator of revenue growth. This progress reflects the rebuilding of o

    4/28/25 5:00:00 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NRC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by National Research Corporation

    SC 13G/A - NATIONAL RESEARCH CORP (0000070487) (Subject)

    11/13/24 4:05:19 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G/A filed by National Research Corporation (Amendment)

    SC 13G/A - NATIONAL RESEARCH CORP (0000070487) (Subject)

    3/8/24 4:05:05 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13D/A filed by National Research Corporation (Amendment)

    SC 13D/A - NATIONAL RESEARCH CORP (0000070487) (Subject)

    3/5/24 4:31:31 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care